Pluri

Pluri is a biotechnology company specializing in 3D cell-expansion technology to develop and manufacture cell-based products. The company focuses on creating advanced solutions across multiple sectors, including regenerative medicine, food-tech, and agriculture. Its proprietary platform enables the scalable production of high-quality cell therapies and other cell-based applications, addressing complex biological challenges with industrial precision.

The company was founded on May 11, 2001, by Shai Meretzki. Meretzki’s foundational insight stemmed from his Ph.D. research at the Technion – Israel Institute of Technology, where he utilized a stem cell patent to initiate the development of robust cell-based solutions. This scientific genesis positioned Pluri, initially known as Pluristem Therapeutics, at the forefront of cellular therapy innovation.

Pluri targets partnerships within the regenerative medicine and food-tech industries, leveraging its unique technological capabilities. The company's overarching vision is to contribute to global well-being and sustainability by developing and commercializing cell-based solutions that offer tangible benefits across health and environmental applications. Pluri continues to advance its platform to meet future demands for biological products.